Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Maurizio Zangari

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Zangari, Maurizio

Item TypeName
Academic Article MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants.
Academic Article Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen.
Academic Article Treatment of multiple myeloma.
Academic Article Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma.
Academic Article Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Academic Article Immunomodulatory drugs in multiple myeloma.
Academic Article Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
Academic Article A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Academic Article Thrombosis in multiple myeloma.
Academic Article Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Academic Article Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.
Academic Article Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
Academic Article Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.
Academic Article Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Academic Article Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Academic Article Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Academic Article Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone.
Academic Article Impact of bortezomib on bone health in myeloma: a review of current evidence.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Concept Antineoplastic Agents
Concept Antineoplastic Agents, Alkylating
Concept Antineoplastic Agents, Hormonal
Academic Article Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.
Academic Article A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Academic Article Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Search Criteria
  • Antineoplastic Agents